Navigation Links
YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
Date:1/26/2010

MISSISSAUGA, ON, Jan. 26 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX:YM), announced that the FDA has advised the Company that it may now enroll patients at US clinical sites into two ongoing randomized, double-blind Phase II trials of its lead product, nimotuzumab. One of the two trials is in non-small-cell lung cancer (NSCLC) patients who are ineligible for curative treatment and being treated palliatively and the other in patients with brain metastases from NSCLC. Current NSCLC palliative treatment and treatment for brain metastases is radiation alone.

The current trial designs were informed by previous trials with nimotuzumab in the same indications. Previous palliative data were presented at ASCO 2008 (Abstract 3037, Bebb, G) and brain metastases randomized data at EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics, 2008 (Poster 505, Macias, A).

YM BioSciences announced on August 10, 2009 that its wholly-owned subsidiary, YM BioSciences USA Inc. (YM-USA) received a license from the US Department of the Treasury's Office of Foreign Assets Control (OFAC) that lifted the limitation on the development of nimotuzumab in the USA for patients with solid tumor cancers.

"Nimotuzumab has been demonstrating efficacy in trials throughout the world and this clearance from the FDA is an important milestone in our US development program," said David Allan, Chairman & CEO of YM BioSciences Inc. "We are very pleased that US patients will now have the opportunity to receive nimotuzumab and that a broader group of US oncologists will gain experience with it. While the rarity of any of the severe toxicities generally attributed to this class of drug has been a challenge for the credibility of nimotuzumab's efficacy, the growing recognition of o
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... -- Research and Markets has announced the ... & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market ... The global molecular biology enzymes market ... expected to grow at a CAGR of 13.74% to ... & reagents find applications in a large number of ...
(Date:8/22/2014)... Angeles (PRWEB) August 22, 2014 ... age-defying products, is in the spotlight again. Nerium ... cream and its NeriumFirmTM Body Contouring Cream to ... by Backstage Creations during the 66th Primetime Emmy® ... patented NAE-8® extract, third-party clinical trials show that ...
(Date:8/22/2014)... “Our nation's healthcare system is broken, ... Furthermore, every governmental and professional entity that has ... of unorganized dysfunction shares in that enormous blame. ... as a device to use in an effort ... have accumulated through the years leading to the ...
(Date:8/21/2014)... PA & Rockville, MD (PRWEB) August 21, 2014 ... (ITI) is making progress in its development of ... to Japanese red cedar pollen. Phase IC studies began ... a real solution to hay fever. , The Japanese ... over 35 million people in Japan. Mountain Cedar pollen ...
Breaking Biology Technology:Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 35 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4
... Combination of Panzem(R) NCD and Avastin(R) May ... 28 EntreMed, Inc.,(Nasdaq: ENMD ), ... treatment of cancer and inflammatory diseases, today,announced ... Phase 2 multi-center,study combining Panzem(R) NCD with ...
... PARIS, January 28 Sanofi-aventis announced,today that ... approved for marketing in Japan by the ... prevention of venous thromboembolism (VTE) in patients,undergoing ... as total hip,replacement, total knee replacement and ...
... Inc.,(NYSE: FRX ), Forest Laboratories Holdings, Ltd., ... GmbH announced that they have filed a second,lawsuit ... of Delaware against,additional companies for infringement of U.S. ... Forest,s Namenda(R) product. The defendants,named in the lawsuit ...
Cached Biology Technology:EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study 2EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study 3EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study 4Clexane(R)/Lovenox(R) Approved in Japan 2Clexane(R)/Lovenox(R) Approved in Japan 3Clexane(R)/Lovenox(R) Approved in Japan 4Clexane(R)/Lovenox(R) Approved in Japan 5Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement 2
(Date:8/22/2014)... tea polyphenols are strong antioxidants and can ... spinal cord neurons against oxidative stress? Jianbo ... Hospital of Liaoning Medical University, China discovered ... stress and inhibit neuronal apoptosis, indicating green ... spinal cord neurons under oxidative stress. The ...
(Date:8/22/2014)... American consumers will finally be able to purchase fuel ... as zero-emissions vehicles, most of the cars will run ... that contributes to global warming. , Now scientists at ... uses an ordinary AAA battery to produce hydrogen by ... through two electrodes that split liquid water into hydrogen ...
(Date:8/21/2014)... Ga. An international team of scientists including researchers from ... Brassica napus commonly known as canolain the journal Science ... the plant, which is used widely in farming and industry. ... its native Europe, but the winter crop is increasingly cultivated ... its naturally low levels of saturated fat and rich supply ...
Breaking Biology News(10 mins):Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Canola genome sequence reveals evolutionary 'love triangle' 2
... HUNTSVILLE, TX (Feb. 21, 2012)-- An assistant ... Criminal Justice is working to unlock the mysteries ... play on criminal and antisocial behavior. "Biosocial ... behavior," said Dr. Brian Boutwell. "It involves aspects ...
... 2012A team of researchers has found a way to ... to be available, despite the potential attack of Xylella ... poses a significant threat to the California wine industry,s ... Laboratory (LANL), University of California at Davis (UCD), and ...
... prospective study of ethnic differences in the symptoms of ... background have more delayed language, communication and gross motor ... the Kennedy Krieger Institute concluded that subtle developmental delays ... severe symptoms develop. While the prevalence of autism ...
Cached Biology News:Are there biosocial origins for antisocial behavior? 2More grapes, less wrath: Hybrid antimicrobial protein protects grapevines from pathogen 2New study shows minority toddlers with autism are more delayed than affected Caucasian peers 2New study shows minority toddlers with autism are more delayed than affected Caucasian peers 3
... Tissue Array (MSTA) slides were designed to study ... from multiple species. Tissue slices from three ... which can then be treated as a single ... in situ hybridization. This format allows ...
... Clear yellow solution. In ... thimerosal, and other proprietary ... Diluent formulated to stabilize ... antibody conjugates at high ...
... used to predict the melting ... up to 3,200 bases, which ... primers and GC clamps for ... gel electrophoresis (DGGE), constant denaturing ...
... Mini-Sub cell GT cell and PowerPac basic power ... of nucleic acids in agarose gels. The Mini-Sub ... with cables and electrodes, a 7 x 7 ... casting gates, and two 1.5 mm fixed-height combs ...
Biology Products: